This report provides all the information you require to better understand Bristol-Myers Squibb and its partnering interests and activities over the past seven years.
Global biopharmaceutical company Bristol-Myers Squib has today announced that is has made an $885 million offer to acquire ZymoGenetics for a total of $885 million in cash.
Sorry, your search returned no results.
Bristol-Myers Squibb Company and Lonza announced a multi-year expansion of their existing biologics manufacturing agreement.
Immuneering Corporation has entered into a pharma alliance agreement to expand its existing relationship with Bristol-Myers Squibb for the use of Immuneering’s proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines.
IncellDx have entered into an pharma partnering agreement with Bristol-Myers Squibb Company to the development of an assay for potential application in a molecular companion diagnostic.
Bristol-Myers Squibb Company and Simcere Pharmaceutical have expanded their pharma deals formed in 2010.
Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer announced a pharma partnering clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS(apixaban)
Vanderbilt University and Bristol-Myers Squibb, a top big pharma company have signed a pharma alliances agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson’s disease